Clinical Trials Logo

Filter by:
NCT ID: NCT05436093 Recruiting - Solid Tumor Clinical Trials

CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Start date: June 23, 2022
Phase: N/A
Study type: Interventional

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

NCT ID: NCT05435872 Recruiting - Clinical trials for Artificial Intelligence

Gastrointestinal Endoscopy Artificial Intelligence Cloud Platform in Gastrointestinal Endoscopy Screening

Start date: July 9, 2022
Phase: N/A
Study type: Interventional

Study objective: To establish a quality control system for gastrointestinal endoscopy based on artificial intelligence technology and an auxiliary diagnosis system that can perform lesion identification, improving the detection rate of early gastrointestinal cancer while standardizing, normalizing, and homogenizing the endoscopic treatment in primary hospitals (including some of the primary hospitals, which are participating in Beijing-Tianjin-Hebei Gastrointestinal Endoscopy Medical Consortium) under Gastrointestinal Endoscopy Artificial Intelligence Cloud Platform as the hardware base. Study design: This study is a prospective, multi-center, real-world study.

NCT ID: NCT05435716 Recruiting - Clinical trials for Peripheral Arterial Disease

Clinical Trial of C-Wave™ Peripheral Lithoclasty System Catheter System

Start date: August 5, 2021
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of peripheral shock catheter system in peripheral arterial angioplasty.This trial is a prospective, multicenter, open, randomized, parallel controlled and superior clinical trial. Select ≥3 hospitals with the qualification of national clinical trial institutions as clinical trial centers, and plan to enroll a total of 120 subjects. The ratio of subjects in the trial group and the control group is 1: 1 (60 in the trial group and 60 in the control group). This study mainly includes four stages: the screening (baseline) period (-14 ~0 days), the operation day (the day of treatment), the postoperative visit (0~7days ) and the 30-day follow-up (30 ±7days ).

NCT ID: NCT05435651 Recruiting - Clinical trials for Attention Deficit Hyperactivity Disorder

Digital Therapy for Treating Attention Deficit Hyperactivity Disorder

Start date: July 16, 2022
Phase: N/A
Study type: Interventional

This study is designed to explore the effect of Multitask game-based digital therapy versus Schulte Grid digital game on attentional functioning (measured by the TOVA), ADHD symptoms, executive functioning, and clinical impairment, in children diagnosed with ADHD. Investigators will also evaluate the safety of digital therapy for intervention treatment of childhood attention deficit hyperactivity disorder.

NCT ID: NCT05435612 Recruiting - Unilateral Deafness Clinical Trials

Evaluation of Rehabilitation Results in the Single-sided Deafness With Cochlear Implantation

Start date: July 5, 2022
Phase: N/A
Study type: Interventional

Single-sided deafness (SSD) refers to severe to profound sensorineural hearing loss on one side (average pure-tone hearing threshold≥70 dB HL at 0.5, 1, 2, and 4kHz) while the opposite side maintains normal hearing or mild hearing loss (30 dB HL). Asymmetrical hearing loss (AHL) refers to severe to profound sensorineural hearing loss in the bad ear (average pure-tone hearing threshold≥70 dB HL at 0.5, 1, 2, and 4kHz) and mild to moderate hearing loss in the contralateral ear. Moderate hearing loss (30≤mean pure-tone hearing threshold≤55dBHL). It is generally acknowledged that SSD is a particular clinical manifestation of AHL. The number of people who have hearing loss accounts for 5.3% of the total population, with children for 9%. According to the Second National Sampling Survey on Disabled Persons, China has 27.8 million people with hearing disabilities. The incidence of SSD adults in the United States is 7.2%, with 60,000 new cases per year, compared with 7,500 new patients with SSD annually in the UK. The incidence of SSD in neonates is 0.04%-0.34%, and it ranges from 0.1% to 0.5% in children and adolescents. The etiology of congenital SSD is primarily unknown, which is related to genes. Among the causes of acquired SSD, sudden deafness is the most common. Other causes include head trauma, Meniere's disease, labyrinthitis, unilateral acoustic neuroma, middle ear surgery, ototoxic drug exposure, Virus infection, noise-induced deafness, senile deafness, etc. SSD and AHL impede intellectual development and speech development in children and adolescents, which is associated with the side of hearing loss. For example, children with right-sided hearing loss have relatively poor language learning, logical thinking, and divergent thinking. In contrast, children with left-sided hearing loss have weaker analytical, comprehensive and visual memory abilities and relatively poor spatial imagination and visual-motor coordination. In addition, the lack of long-term monaural listening and sound source localization makes SSD children require excessive concentration, which is prone to fatigue and behavioral problems, and their academic performance is lower than that of normal children.

NCT ID: NCT05435274 Recruiting - Clinical trials for Advanced Non-Small-Cell Lung Cancer

Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

Start date: September 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

HS-10376 is an oral, highly selective, small molecular inhibitor of EGFR/HER2 Exon 20 insertion mutation. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10376 in Chinese advanced Non-Small Cell Lung Cancer (NSCLC) patients.

NCT ID: NCT05435248 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Start date: March 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.

NCT ID: NCT05434507 Recruiting - Clinical trials for Tricuspid Regurgitation

Feasibility Study of Treating Tricuspid Regurgitation With K-ClipTM Transcatheter Annuloplasty System

Start date: September 16, 2021
Phase: N/A
Study type: Interventional

Evaluate the effectiveness and safety of the transcatheter tricuspid annuloplasty system manufactured by Shanghai Huihe Medical Technology Co., Ltd. for the treatment of patients with moderate-severe or worse tricuspid regurgitation

NCT ID: NCT05434325 Recruiting - Kidney Diseases Clinical Trials

TESTING -ON Post-Trial ObservatioNal Cohort Study

TESTING-ON
Start date: December 7, 2022
Phase:
Study type: Observational

The primary aim of this study is to extend follow up of TESTING study participants and to assess the long-term effects of a 6-9-month course of oral methylprednisolone on End Stage Kidney Disease (ESKD), according to dose (full-dose vs reduced-dose), ethnicity (Chinese vs other) and kidney function (eGFR above and below 60 mL/min/1.73m2).

NCT ID: NCT05434312 Recruiting - Clinical trials for Chronic Myelogenous Leukemia

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Start date: March 29, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.